FindTrial
Sign In

Efficacy and safety of pregabalin combined with duloxetine in the treatment of fibromyalgia syndrome

Efficacy and safety of pregabalin combined with duloxetine in the treatment of fibromyalgia syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059235
Enrollment
Unknown
Registered
2022-04-27
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Interventions

None listed

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Male and female outpatients between the ages of 20 and 75 years, diagnosed with FM according to the 2016 revision of the American College of Rheumatology's 2010/2011 FM diagnostic criteria, and with a pain score of =4 (VAS) were included.

Exclusion criteria

Exclusion criteria: Severe heart and lung disease; severe hepatic and renal insufficiency; previous history of mental illness, opioid abuse; possible drug allergy related to the trial; unable to obtain informed consent

Design outcomes

Primary

MeasureTime frame
Pain;Sleep;—

Secondary

MeasureTime frame
Improvements in quality of life;—

Countries

China

Contacts

Public ContactXIAO Hong
xiaohonghuaxi@126.com18980601980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026